Literature DB >> 2027482

Persistent neurotoxicity of systemically administered interferon-alpha.

C A Meyers1, R S Scheibel, A D Forman.   

Abstract

Fourteen cancer patients had evidence of persistent neurotoxicity of interferon-alpha therapy long after their treatment was discontinued. Although most of the cognitive symptoms were mild to moderate in severity, they were incapacitating to these individuals in their usual work. The neuropsychological test abnormalities were not attributable to subsequent therapy, disease status, or other medical problems. The pattern of deficits was consistent with frontal-subcortical dysfunction. Of the four patients who had follow-up assessment, two had improved and two had deteriorated. These findings suggest that in some cases interferon neurotoxicity is not reversible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2027482     DOI: 10.1212/wnl.41.5.672

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Effect of interferon-alpha on DOI-induced wet-dog shakes in rats.

Authors:  A Kugaya; A Kagaya; Y Uchitomi; N Yokota; S Yamawaki
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Cognitive impairment in hepatitis C patients on antiviral therapy.

Authors:  Jessica Irwin; Norah Terrault
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

Review 3.  HIV Eradication Strategies: Implications for the Central Nervous System.

Authors:  Rebecca T Veenhuis; Janice E Clements; Lucio Gama
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

Review 4.  Cancer-treatment-induced neurotoxicity--focus on newer treatments.

Authors:  Jacqueline B Stone; Lisa M DeAngelis
Journal:  Nat Rev Clin Oncol       Date:  2015-09-22       Impact factor: 66.675

5.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain.

Authors:  S Abe; T Hori; T Suzuki; A Baba; H Shiraishi; T Yamamoto
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

7.  Acute third cranial nerve ophthalmoplegia: possible pathogenesis from alpha-II-interferon treatment.

Authors:  L Pacifici; F Passarelli; G Papa; L Cannone; P M Rossini
Journal:  Ital J Neurol Sci       Date:  1993-10

Review 8.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.

Authors:  Andrew H Miller; Sonia Ancoli-Israel; Julienne E Bower; Lucile Capuron; Michael R Irwin
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

9.  Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping.

Authors:  A Pace; A Pietrangeli; L Bove; M Rosselli; M Lopez; B Jandolo
Journal:  Ital J Neurol Sci       Date:  1994-10

10.  Toxic effect of intraventricular interferon-alpha in subacute sclerosing panencephalitis.

Authors:  C Cianchetti; A L Fratta; F Muntoni; G Marrosu; M G Marrosu
Journal:  Ital J Neurol Sci       Date:  1994-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.